List of Figures
Figure 2.1. Research Methodology: Project Methodology
Figure 2.2. Research Methodology: Forecast Methodology
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1. Executive Summary: Market Landscape
Figure 4.2. Executive Summary: Partnerships and Collaborations
Figure 4.3. Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1. Advantage of GLP-1 Drugs
Figure 5.2. Challenges Associated with GLP-1 Drugs
Figure 5.3. Mechanisms of Action of GLP-1 Drugs
Figure 6.1. GLP-1 Drugs: Distribution by Status of Development
Figure 6.2. GLP-1 Drugs: Distribution by Type of Molecule
Figure 6.3. GLP-1 Drugs: Distribution by Active Compound Used
Figure 6.4. GLP-1 Drugs: Distribution by Type of Agonist
Figure 6.5. GLP-1 Drugs: Distribution by Route of Administration
Figure 6.6. GLP-1 Drugs: Distribution by Dosing Frequency
Figure 6.7. GLP-1 Drugs: Distribution by Type of Therapy
Figure 6.8. GLP-1 Drugs: Distribution by Target Indication
Figure 6.9. GLP-1 Drugs: Distribution by Therapeutic Area
Figure 6.10. GLP-1 Drugs Developer: Distribution by Year of Establishment
Figure 6.11. GLP-1 Drugs Developer: Distribution by Company Size
Figure 6.12. GLP-1 Drugs Developer: Distribution by Location of Headquarters
Figure 6.13. GLP-1 Drugs Developer: Distribution by Location of Headquarters (Country) and Status of Development
Figure 6.14. Most Active Developers: Distribution by Number of Drugs
Figure 7.1. AstraZeneca: Annual Revenues, FY 2021-FY 2023 (USD Billion)
Figure 7.2. D&D Pharmatech: Annual Revenues, FY 2021-FY 2023 (Korean Won Billion)
Figure 7.3. Eli Lilly: Annual Revenues, FY 2021-FY 2023 (USD Billion)
Figure 7.4. Novo Nordisk: Annual Revenues, FY 2021-FY 2023 (DKK Billion)
Figure 7.5. Pfizer: Annual Revenues, FY 2021-FY 2023 (USD Billion)
Figure 7.6. Sanofi: Annual Revenues, FY 2021-FY 2023 (EUR Billion)
Figure 7.7. Tonghua Dongbao Pharmaceutical: Annual Revenues, FY 2021-FY 2023 (RMB Billion)
Figure 9.1. Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Distribution by Focus Area
Figure 9.4. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 9.5. Most Active Players: Distribution by Number of Partnerships
Figure 9.6. Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Deals
Figure 9.7. Partnerships and Collaborations: Distribution by Local and International Deals
Figure 10.1. GLP-1 Drugs: Market Drivers
Figure 10.2. GLP-1 Drugs: Market Restraints
Figure 10.3. GLP-1 Drugs: Market Opportunities
Figure 10.4. GLP-1 Drugs: Market Challenges
Figure 11.1. Global GLP-1 Market, Historical Trends and Forecasted Estimates, till 2035
Figure 11.2. Global GLP-1 Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Billion)
Figure 11.3. Global GLP-1 Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Billion)
Figure 12.1. GLP-1 Market: Distribution by Type of Molecule, 2020, 2024 and 2035
Figure 12.2. GLP-1 Market for Biologics, till 2035 (USD Billion)
Figure 12.3. GLP-1 Market for Small Molecule, till 2035 (USD Billion)
Figure 13.1. GLP-1 Market: Distribution by Active Compound Used, 2020, 2024 and 2035
Figure 13.2. GLP-1 Market for Dulaglutide, till 2035 (USD Billion)
Figure 13.3. GLP-1 Market for Liraglutide, till 2035 (USD Billion)
Figure 13.4. GLP-1 Market for Orforglipron, till 2035 (USD Billion)
Figure 13.5. GLP-1 Market for Retatrutide, till 2035 (USD Billion)
Figure 13.6. GLP-1 Market for Semaglutide, till 2035 (USD Billion)
Figure 13.7. GLP-1 Market for Survodutide, till 2035 (USD Billion)
Figure 13.8. GLP-1 Market for Tirzepatide, till 2035 (USD Billion)
Figure 13.9. GLP-1 Market for Other Active Compounds, till 2035 (USD Billion)
Figure 14.1. GLP-1 Market: Distribution by Type of GLP-1 Agonist Drug, 2020, 2024 and 2035
Figure 14.2. GLP-1 Market for Long-acting GLP-1 Agonist, till 2035 (USD Billion)
Figure 14.3. GLP-1 Market for Short-acting GLP-1 Agonist, till 2035 (USD Billion)
Figure 15.1. GLP-1 Market: Distribution by GLP-1 Agonist, 2020, 2024 and 2035
Figure 15.2. GLP-1 Market for Single-agonist, till 2035 (USD Billion)
Figure 15.3. GLP-1 Market for Dual-agonist, till 2035 (USD Billion)
Figure 15.4. GLP-1 Market for Tri-agonist, till 2035 (USD Billion)
Figure 16.1. GLP-1 Market: Distribution by Route of Administration, 2020, 2024 and 2035
Figure 16.2. GLP-1 Market for Oral, till 2035 (USD Billion)
Figure 16.3. GLP-1 Market for Parenteral, till 2035 (USD Billion)
Figure 17.1. GLP-1 Market: Distribution by Target Indication, 2020, 2024 and 2035
Figure 17.2. GLP-1 Market for Alzheimer’s Disease, till 2035 (USD Billion)
Figure 17.3. GLP-1 Market for Non-alcoholic Steatohepatitis, till 2035 (USD Billion)
Figure 17.4. GLP-1 Market for Obesity, till 2035 (USD Billion)
Figure 17.5. GLP-1 Market for Sleep Apnea, till 2035 (USD Billion)
Figure 17.6. GLP-1 Market for Type 2 Diabetes, till 2035 (USD Billion)
Figure 18.1. GLP-1 Market: Distribution by Geography, 2020, 2024 and 2035
Figure 18.2. GLP-1 Market in North America, till 2035 (USD Billion)
Figure 18.3. GLP-1 Market in Europe, till 2035 (USD Billion)
Figure 18.4. GLP-1 Market in Asia Pacific, till 2035 (USD Billion)
Figure 18.5. GLP-1 Market in Latin America, till 2035 (USD Billion)
Figure 19.1. Approved GLP-1 Drug, Feisumei (Benaglutide) Sales Forecast, till 2035 (USD Billion)
Figure 19.2. Approved GLP-1 Drug, Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast, till 2035 (USD Billion)
Figure 19.3. Approved GLP-1 Drug, Mounjaro (Tirzepatide) Sales Forecast, till 2035 (USD Billion)
Figure 19.4. Approved GLP-1 Drug, Ozempic (Semaglutide Subcutaneous) Sales Forecast, till 2035 (US D Billion)
Figure 19.5. Approved GLP-1 Drug, Rybelsus (Semaglutide Oral) Sales Forecast, till 2035 (USD Billion)
Figure 19.6. Approved GLP-1 Drug, Saxenda (Liraglutide) Sales Forecast, till 2035 (USD Billion)
Figure 19.7. Approved GLP-1 Drug, Trulicity (Dulaglutide) Sales Forecast, till 2035 (USD Billion)
Figure 19.8. Approved GLP-1 Drug, Victoza (Liraglutide) Sales Forecast, till 2035 (USD Billion)
Figure 19.9. Approved GLP-1 Drug, Wegovy (Semaglutide Subcutaneous) Sales Forecast, till 2035 (USD Billion)
Figure 19.10. Approved GLP-1 Drug, XULTOPHY (Insulin Degludec / Liraglutide ) Sales Forecast, till 2035 (USD Billion)
Figure 19.11. Approved GLP-1 Drug, Zepbound (Tirzepatide) Sales Forecast, till 2035 (USD Billion)
Figure 19.12. Phase III GLP-1 Drug, GMA102 / Glutazumab Sales Forecast, till 2035 (USD Billion)
Figure 19.13. Phase III GLP-1 Drug, JY09 Sales Forecast, till 2035 (USD Billion)
Figure 19.14. Phase III GLP-1 Drug, LY3298176 / Tirzepatide Sales Forecast, till 2035 (USD Billion)
Figure 19.15. Phase III GLP-1 Drug, Mazdutide / LY3305677/ IBI-362 Sales Forecast, till 2035 (USD Billion)
Figure 19.16. Phase III GLP-1 Drug, Orforglipron / LY3502970 Sales Forecast, till 2035 (USD Billion)
Figure 19.17. Phase III GLP-1 Drug, PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast, till 2035 (USD Billion)
Figure 19.18. Phase III GLP-1 Drug, Retatrutide / LY3437943 Sales Forecast, till 2035 (USD Billion)
Figure 19.19. Phase III GLP-1 Drug, Semaglutide Oral Sales Forecast, till 2035 (USD Billion)
Figure 19.20. Phase III GLP-1 Drug, Semaglutide Subcutaneous Sales Forecast, till 2035 (USD Billion)
Figure 19.21. Phase III GLP-1 Drug, Survodutide / BI 456906 Sales Forecast, till 2035 (USD Billion)
Figure 19.22. Phase III GLP-1 Drug, XW003 / Ecnoglutide Sales Forecast, till 2035 (USD Billion)
Figure 19.23. Phase III GLP-1 Drug, YN011-isupaglutide Sales Forecast, till 2035 (USD Billion)
Figure 20.1. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2020 (USD Billion))
Figure 20.2. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2024 (USD Billion))
Figure 20.3. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales estimated in 2035 (USD Billion))
List of Tables
Table 6.1. List of GLP-1 Drugs
Table 6.2. List of GLP-1 Drug Developers
Table 7.1. AstraZeneca: Pipeline Portfolio
Table 7.2. AstraZeneca: Recent Developments and Future Outlook
Table 7.3. D&D Pharmatech: Pipeline Portfolio
Table 7.4. D&D Pharmatech: Recent Developments and Future Outlook
Table 7.5. Eli Lilly: Pipeline Portfolio
Table 7.6. Eli Lilly: Recent Developments and Future Outlook
Table 7.7. Novo Nordisk: Pipeline Portfolio
Table 7.8. Novo Nordisk: Recent Developments and Future Outlook
Table 7.9. Pfizer: Pipeline Portfolio
Table 7.10. Pfizer: Recent Developments and Future Outlook
Table 7.11. Sanofi: Pipeline Portfolio
Table 7.12. Sanofi: Recent Developments and Future Outlook
Table 7.13. Tonghua Dongbao Pharmaceutical: Pipeline Portfolio
Table 7.14. Tonghua Dongbao Pharmaceutical: Recent Developments and Future Outlook
Table 7.15. Vivani: Pipeline Portfolio
Table 7.16. Vivani: Recent Developments and Future Outlook
Table 8.1. Biolingus: Pipeline Portfolio
Table 8.2. Boehringer Ingelheim: Pipeline Portfolio
Table 8.3. Gmax Biopharm: Pipeline Portfolio
Table 8.4. Hanmi Pharmaceutical: Pipeline Portfolio
Table 8.5. PegBio: Pipeline Portfolio
Table 8.6. QL Biopharma: Pipeline Portfolio
Table 8.7. Roche: Pipeline Portfolio
Table 8.8. Sciwind Biosciences: Pipeline Portfolio
Table 8.9. Viking Therapeutics: Pipeline Portfolio
Table 8.10. vTv Therapeutics: Pipeline Portfolio
Table 9.1. GLP-1 Drug Market: List of Partnerships and Collaborations, Since 2020
Table 11.1. List of GLP-1 Drugs Forecasted
Table 21.1. GLP-1 Drugs: Distribution by Status of Development
Table 21.2. GLP-1 Drugs: Distribution by Type of Molecule
Table 21.3. GLP-1 Drugs: Distribution by Active Compound Used
Table 21.4. GLP-1 Drugs: Distribution by Type of Agonist
Table 21.5. GLP-1 Drugs: Distribution by Route of Administration
Table 21.6. GLP-1 Drugs: Distribution by Dosing Frequency
Table 21.7. GLP-1 Drugs: Distribution by Type of Therapy
Table 21.8. GLP-1 Drugs: Distribution by Target Indication
Table 21.9. GLP-1 Drugs: Therapeutic Area
Table 21.10. GLP-1 Drugs Developer: Distribution by Year of Establishment
Table 21.11. GLP-1 Drugs Developer: Distribution by Company Size
Table 21.12. GLP-1 Drugs Developer: Distribution by Location of Headquarters
Table 21.13. GLP-1 Drugs Developer: Distribution by Location of Headquarters (Country) and Status of Development
Table 21.14. Most Active Developers: Distribution by Number of Drugs
Table 21.15. AstraZeneca: Annual Revenues, FY 2021-FY 2023 (USD Billion)
Table 21.16. D&D Pharmatech: Annual Revenues, FY 2021-FY 2023 (KRW Billion)
Table 21.17. Eli Lilly: Annual Revenues, FY 2021-FY 2023 (USD Billion)
Table 21.18. Novo Nordisk: Annual Revenues, FY 2021-FY 2023 (DKK Billion)
Table 21.19. Pfizer: Annual Revenues, FY 2021-FY 2023 (USD Billion)
Table 21.20. Sanofi: Annual Revenues, FY 2021-FY 2023 (EUR Billion)
Table 21.21. Tonghua Dongbao Pharmaceutical: Annual Revenues, FY 2021-FY 2023 (RMB Billion)
Table 21.22. Partnerships and Collaborations: Distribution by Year of Partnership
Table 21.23. Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.24. Partnerships and Collaborations: Distribution by Focus Area
Table 21.25. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 21.26. Most Active Players: Distribution by Number of Partnerships
Table 21.27. Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Deals
Table 21.28. Partnerships and Collaborations: Distribution by Local and International Deals
Table 21.29. Global GLP-1 Market, Historical Trends (2020-2023) (USD Billion)
Table 21.30. Global GLP-1 Market, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario, (USD Billion)
Table 21.31. GLP-1 Market: Distribution by Type of Molecule, 2020, 2024 and 2035
Table 21.32. GLP-1 Market for Biologics, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.33. GLP-1 Market for Small Molecule, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.34. GLP-1 Market: Distribution by Active Compound Used, 2020, 2024 and 2035
Table 21.35. GLP-1 Market for Dulaglutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.36. GLP-1 Market for Liraglutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.37. GLP-1 Market for Orforglipron, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.38. GLP-1 Market for Retatrutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.39. GLP-1 Market for Semaglutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.40. GLP-1 Market for Survodutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.41. GLP-1 Market for Tirzepatide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.42. GLP-1 Market for Other Active Compounds, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.43. GLP-1 Market: Distribution by Type of GLP-1 Agonist Drug, 2020, 2024 and 2035
Table 21.44. GLP-1 Market for Long-acting GLP-1 Agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.45. GLP-1 Market for Short-acting GLP-1 Agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.46. GLP-1 Market: Distribution by GLP-1 Agonist, 2020, 2024 and 2035
Table 21.47. GLP-1 Market for Single-agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.48. GLP-1 Market for Dual-agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.49. GLP-1 Market for Tri-agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.50. GLP-1 Market: Distribution by Route of Administration, 2020, 2024 and 2035
Table 21.51. GLP-1 Market for Oral Route, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.52. GLP-1 Market for Parenteral Route, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.53. GLP-1 Market: Distribution by Target Indication, 2020, 2024 and 2035
Table 21.54. GLP-1 Market for Alzheimer’s Disease, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.55. GLP-1 Market for Non-alcoholic Steatohepatitis, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.56. GLP-1 Market for Obesity, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.57. GLP-1 Market for Sleep Apnea, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.58. GLP-1 Market for Type 2 Diabetes, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.59. GLP-1 Market: Distribution by Geography, 2020, 2024 and 2035
Table 21.60. GLP-1 Market in North America, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.61. GLP-1 Market in US, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.62. GLP-1 Market in Canada, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.63. GLP-1 Market in Europe, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.64. GLP-1 Market in Germany, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.65. GLP-1 Market in UK, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.66. GLP-1 Market in France, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.67. GLP-1 Market in Italy, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.68. GLP-1 Market in Spain, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.69. GLP-1 Market in Asia Pacific, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.70. GLP-1 Market in China, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.71. GLP-1 Market in Japan, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.72. GLP-1 Market in Australia, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.73. GLP-1 Market in South Korea, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.74. GLP-1 Market in Latin America, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.75. GLP-1 Market in Brazil, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.76. GLP-1 Market in Argentina, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.77. Approved GLP-1 Drug, Feisumei (Benaglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.78. Approved GLP-1 Drug, Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.79. Approved GLP-1 Drug, Mounjaro (Tirzepatide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.80. Approved GLP-1 Drug, Ozempic (Semaglutide Subcutaneous) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.81. Approved GLP-1 Drug, Rybelsus (Semaglutide Oral) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.82. Approved GLP-1 Drug, Saxenda (Liraglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.83. Approved GLP-1 Drug, Trulicity (Dulaglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.84. Approved GLP-1 Drug, Victoza (Liraglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.85. Approved GLP-1 Drug, Wegovy (Semaglutide Subcutaneous) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.86. Approved GLP-1 Drug, XULTOPHY (Insulin Degludec / Liraglutide ) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.87. Approved GLP-1 Drug, Zepbound (Tirzepatide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.88. Phase III GLP-1 Drug, GMA102 / Glutazumab Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.89. Phase III GLP-1 Drug, JY09 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.90. Phase III GLP-1 Drug, LY3298176 / Tirzepatide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.91. Phase III GLP-1 Drug, Mazdutide / LY3305677/ IBI-362 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.92. Phase III GLP-1 Drug, Orforglipron / LY3502970 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.93. Phase III GLP-1 Drug, PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.94. Phase III GLP-1 Drug, Retatrutide / LY3437943 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.95. Phase III GLP-1 Drug, Semaglutide Oral Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.96. Phase III GLP-1 Drug, Semaglutide Subcutaneous Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.97. Phase III GLP-1 Drug, Survodutide / BI 456906 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.98. Phase III GLP-1 Drug, XW003 / Ecnoglutide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.99. Phase III GLP-1 Drug, YN011-isupaglutide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.100. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2020, Conservative, Base and Optimistic Scenario (USD Billion))
Table 21.101. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2024, Conservative, Base and Optimistic Scenario (USD Billion))
Table 21.102. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales estimated in 2035, Conservative, Base and Optimistic Scenario (USD Billion))